Last reviewed · How we verify
Clostridium butyricum capsule
Clostridium butyricum is a live biotherapeutic that colonizes the gut and produces butyrate, a short-chain fatty acid that supports intestinal barrier function and modulates immune homeostasis.
Clostridium butyricum is a live biotherapeutic that colonizes the gut and produces butyrate, a short-chain fatty acid that supports intestinal barrier function and modulates immune homeostasis. Used for Diarrhea-predominant irritable bowel syndrome, Antibiotic-associated diarrhea, Inflammatory bowel disease.
At a glance
| Generic name | Clostridium butyricum capsule |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | Live biotherapeutic agent |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
C. butyricum is a gram-positive, anaerobic bacterium that ferments carbohydrates to produce butyrate, which serves as an energy source for colonocytes and strengthens the intestinal epithelial barrier. Butyrate also promotes the differentiation of regulatory T cells and reduces pro-inflammatory cytokine production, thereby restoring dysbiotic microbiota balance and reducing intestinal inflammation.
Approved indications
- Diarrhea-predominant irritable bowel syndrome
- Antibiotic-associated diarrhea
- Inflammatory bowel disease
Common side effects
- Abdominal discomfort
- Flatulence
- Diarrhea
Key clinical trials
- Clostridium Butyricum in Stenosing Crohn's Desease (PHASE1, PHASE2)
- The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma (PHASE4)
- The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer (PHASE4)
- A Probiotic Based Intervention in Pregnancies Complicated by GDM (PHASE2)
- Role of Akkermansia Muciniphila in Acne Vulgaris (EARLY_PHASE1)
- OsteoPreP: Food Supplements for Postmenopausal Bone Health (PHASE4)
- CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer (PHASE1)
- Next-Generation Synbiotic in Individuals With Overweight or Obesity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clostridium butyricum capsule CI brief — competitive landscape report
- Clostridium butyricum capsule updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI